Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
95 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Iovance Biotherapeutics, Inc.’s names, not what it holds today.
Patents granted
95
95 utility, 1976 to Dec 31, 2025
Granted in 2025
12
Against 15 in 2024 and 5 in 2023
Applications published
187
18 of them in 2025
Names they are printed under
3
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals38
Biotechnology32
Medical technology11
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Iovance Biotherapeutics, Inc. its own name
named as the applicant on its applications, in US
176 publishedIovance Biotherapeutics, Inc. its own name
US, as the owner printed on each patent
11 publishedIóvance Biotherapeutics, Inc. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Dec 16, 2025 | 12,495,791 | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy | Biotechnology | Ióvance Biotherapeutics, Inc. |
| Dec 2, 2025 | 12,485,145 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | Pharmaceuticals | Iovance Biotherapeutics, Inc. |
| Nov 18, 2025 | 12,473,532 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | Biotechnology | Iovance Biotherapeutics, Inc. |
| Oct 28, 2025 | 12,453,697 | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy | Pharmaceuticals | Iovance Biotherapeutics, Inc. |
| Jul 1, 2025 | 12,343,380 | Expansion of TILs utilizing AKT pathways inhibitors | Medical technology | Iovance Biotherapeutics, Inc. |
| Apr 22, 2025 | 12,280,140 | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy | Pharmaceuticals | Iovance Biotherapeutics, Inc. |
| Feb 25, 2025 | 12,233,075 | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same | Pharmaceuticals | Iovance Biotherapeutics, Inc. |
| Feb 18, 2025 | 12,230,379 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy | Medical technology | Iovance Biotherapeutics, Inc. |
| Feb 18, 2025 | 12,230,378 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy | Medical technology | Iovance Biotherapeutics, Inc. |
| Feb 18, 2025 | 12,226,434 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | Pharmaceuticals | Iovance Biotherapeutics, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 18, 2025 | 2025/0380932 | Packaging For Biological Samples | Handling | Iovance Biotherapeutics, Inc. |
| Nov 13, 2025 | 2025/0345364 | CISH GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | Biotechnology | Iovance Biotherapeutics, Inc. |
| Oct 30, 2025 | 2025/0336497 | SYSTEMS AND METHODS FOR DETERMINING THE BENEFICIAL ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES, AND METHODS OF USE THEREOF AND BENEFICIAL ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES, AND METHODS OF USE THEREOF | Medical technology | Iovance Biotherapeutics, Inc. |
| Oct 23, 2025 | 2025/0329428 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | Medical technology | Iovance Biotherapeutics, Inc. |
| Sep 11, 2025 | 2025/0281537 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST | Pharmaceuticals | Iovance Biotherapeutics, Inc. |
| Jul 31, 2025 | 2025/0243458 | METHODS OF USING TUMOR INFILTRATING LYMPHOCYTES IN DOUBLE-REFRACTORY MELANOMA | Medical technology | Iovance Biotherapeutics, Inc. |
| Jul 10, 2025 | 2025/0223371 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS | Biotechnology | Iovance Biotherapeutics, Inc. |
| Jun 12, 2025 | 2025/0188413 | TIL EXPANSION FROM FINE NEEDLE ASPIRATES AND SMALL BIOPSIES | Pharmaceuticals | Iovance Biotherapeutics, Inc. |
| Apr 17, 2025 | 2025/0121009 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | Pharmaceuticals | Iovance Biotherapeutics, Inc. |
| Apr 17, 2025 | 2025/0121008 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | Pharmaceuticals | Iovance Biotherapeutics, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 18 · Biotechnology 14 · Medical technology 10 · Machine tools 1 · Handling 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.